GeneSystem Co

GeneSystem Co Receivables

The Accounts Receivable of GeneSystem Co (363250.KQ) as of Nov 7, 2026 is 87.93 M KRW. In the previous year, Accounts Receivable was 122.22 M KRW — a change of -28.06% (lower).

Receivables

87.93 MKRW

YoY

-28.06%

Last updated:

Accounts Receivable of GeneSystem Co is 2024 87.93 M KRW. Accounts Receivable of GeneSystem Co was 2023 122.22 M KRW. It decreases by -28.06% lower compared to the previous year.

The GeneSystem Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
155.48 M KRW
Jan 1, 2019
270.65 M KRW
Jan 1, 2020
863.17 M KRW
Jan 1, 2021
1.92 B KRW
Jan 1, 2022
494.34 M KRW
Jan 1, 2023
122.22 M KRW
Jan 1, 2024
87.93 M KRW
The GeneSystem Co Receivables history
YEARReceivablesYoY
87.93 MKRW-28.06%
122.22 MKRW-75.28%
494.34 MKRW-74.25%
1.92 BKRW+122.37%
863.17 MKRW+218.93%
270.65 MKRW+74.07%
155.48 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Accounts Receivable of GeneSystem Co is 87.93 M KRW in 2024.

Accounts Receivable of GeneSystem Co changed from 122.22 M KRW to 87.93 M KRW, representing a -28.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's GeneSystem Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GeneSystem Co

All Key Metrics — GeneSystem Co